Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
Pink Sheet: US Pushing Foreign Countries To Pay More For Drugs: Will It Help Americans?
Patients for Affordable Drugs (P4AD), a patient advocacy group, acknowledged a well-designed MFN policy could deliver lower prices for patients and taxpayers. But the group said the 17 existing MFN deals depend on voluntary industry participation and fall short of the systemic reforms. “The terms of the deals remain secret, leaving unanswered questions about the […]
News and Reports
Inside Health Policy: Survey Shows Voters Favor Commitment To MFN Pricing Policies
Patients for Affordable Drugs CEO Merith Basey says the MFN agreements the government has established so far lack the longevity, transparency and oversight to combat a broken system in need of urgent structural change, but it is possible for the policy to be improved. “Since U.S. brand name drugs are priced at least 4 times […]
News and Reports
The Hill: Big Pharma lost in court — Congress must not bail it out
For the last three years, some of the most profitable corporations in the world spent millions of dollars in court attempting to reverse the biggest defeat the pharmaceutical industry suffered in decades. The Supreme Court recently declined even to hear their cases. For these companies, the legal fight is now over. But the pharmaceutical industry’s […]
News and Reports
ICYMI: Merith Basey Op-Ed in The Hill: “Big Pharma lost in court. Congress shouldn't bail them out.”
Basey argues lawmakers should not hand pharmaceutical companies in Congress what they failed to win in court. WASHINGTON, D.C. — Following the Supreme Court’s decision to reject petitions from six major drugmakers seeking to overturn Medicare drug price negotiation, Patients For Affordable Drugs CEO Merith Basey is urging Congress to protect and strengthen the program rather than weaken […]
News and Reports
Epoch Times Video: The Loophole Drug Makers Use to Keep Prices High
News and Reports
IP Watchdog: SCOTUS’ Hikma Ruling Changes the Game for Induced Infringement Pleadings
Patients For Affordable Drugs CEO Merith Basey said in a statement today that the decision “protects an important pathway for bringing lower-cost generic medicines to patients. Had the Court ruled the other way, generic manufacturers could have faced increased legal risk when following the rules established by Congress and the FDA.”
News and Reports
Fierce Pharma: It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
On Thursday, Patients For Affordable Drugs CEO Merith Basey applauded the decision, saying that it “protects an important pathway for bringing lower-cost generic medicines to patients.” “Had the court ruled the other way, generic manufacturers could have faced increased legal risk when following the rules established by Congress and the FDA. That would have meant […]